Isofol has initiated five additional study sites in the ISO-CC-005 study in which Modufolin® is evaluated in colorectal cancer
Isofol Medical AB (publ) announced today that the last one of five additional study sites was initiated in Greece and […]
Corporate Information
Isofol Announces Publication of an Abstract for the 2017 ASCO Annual Meeting
Isofol Medical AB (publ) announces publication of an abstract regarding failure rate of standard rescue after high-dose methotrexate in osteosarcoma
Pareto Securities has notified Isofol Medical AB that stabilisation measures regarding the Company’s shares have been taken
In connection with the offering to acquire newly issued shares in Isofol and the listing on Nasdaq First North Premier
Isofol accepted for presentation of abstract at the 2017 ASCO annual meeting
Isofol Medical AB (publ) announces that an abstract has been accepted to be presented at the American Society of Clinical
Pareto Securities has notified Isofol Medical AB (publ) that stabilisation measures regarding the Company’s shares have been taken
In connection with the offering to acquire newly issued shares in Isofol and the listing on Nasdaq First North Premier
Pareto Securities has notified Isofol Medical AB that stabilisation measures regarding the Company’s shares have been taken
For a complete press release follow the link http://isofol.se/en/ipo/ For additional information, please contact: Anders Rabbe, Managing Director, Isofol Mob: +46 70
Isofol has successfully completed the ISO-MTX-003 study in which Modufolin® is evaluated as rescue therapy
Isofol Medical AB announced today that the study ISO-MTX-003 evaluating Modufolin® as rescue therapy (after two cycles of HDMTX treatment)
Isofol’s largest shareholder and co-founder acquires shares in the company
Isofol Medical AB (publ) announces today that its largest shareholder and co-founder, Bengt Gustavsson, now acquired circa 16 000 shares
Isofol’s Chairman of the Board acquires shares in the company
Isofol Medical AB (publ) announces that its Chairman of the Board, Jan-Eric Österlund, now acquired 15,000 shares in Isofol to
Invitation: Isofol will present it’s contemplated IPO in Stockholm on March 29
In connection with the contemplated IPO of Isofol Medical on Nasdaq First North Premier, we are pleased to invite you